Robert Hoffman - Kintara Therapeutics Independent Director
Director
Mr. Robert E. Hoffman is Chairman of the Board of the Company. Mr. Hoffman has served as a member of Kura Oncology, Inc.s Board of Directors since March 2015. Mr. Hoffman has served as Senior Vice President and Chief Financial Officer of Heron Therapeutics, Inc., a publiclyheld pharmaceutical company since April 2017. Prior to joining Heron Therapeutics, Inc., Mr. Hoffman served as Executive Vice President and Chief Financial Officer of Innovus Pharmaceuticals, Inc., a publiclyheld pharmaceutical company, from September 2016 to April 2017. From July 2015 to September 2016, Mr. Hoffman served as Chief Financial Officer of AnaptysBio, Inc., a publiclyheld biotechnology company. From June 2012 to July 2015, Mr. Hoffman served as the Senior Vice President, Finance and Chief Financial Officer of Arena Pharmaceuticals, Inc., or Arena, a publiclyheld biopharmaceutical company. From August 2011 to June 2012 and previously from December 2005 to March 2011, he served as Arenas Vice President, Finance and Chief Financial Officer and in a number of various roles of increasing responsibility from 1997 to December 2005. From March 2011 to August 2011, Mr. Hoffman served as Chief Financial Officer for Polaris Group, a biopharmaceutical drug company. Mr. Hoffman formerly served as a member of the Board of Directors of CombiMatrix Corporationrationration, a molecular diagnostics company, and MabVax Therapeutics Holdings, Inc., a biopharmaceutical company. Mr. Hoffman serves as a member of the Financial Accounting Standards Boards Small Business Advisory Committee and the steering committee of the Association of Bioscience Financial Officers. Mr. Hoffman formerly served as a director and President, of the San Diego Chapter of Financial Executives International since 2018.
| Age | 52 |
| Tenure | 6 years |
| Professional Marks | CPA |
| Phone | 858-350-4364 |
| Web | http://www.delmarpharma.com |
Kintara Therapeutics Management Efficiency
The company has return on total asset (ROA) of (136.86) % which means that it has lost $136.86 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (316.72) %, meaning that it created substantial loss on money invested by shareholders. Kintara Therapeutics' management efficiency ratios could be used to measure how well Kintara Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Thomas Waechter | NETGEAR | 64 | |
| Martin Cole | Western Digital | 61 | |
| Jocelyn CarterMiller | NETGEAR | 59 | |
| Stuart Randle | Teleflex Incorporated | 61 | |
| George Babich | Teleflex Incorporated | 69 | |
| Stephen Klasko | Teleflex Incorporated | 67 | |
| Matthew Behrent | Asure Software | 46 | |
| Kenton Sicchitano | Analog Devices | 73 | |
| Henry DeNero | Western Digital | 70 | |
| Paula Price | Western Digital | 55 | |
| Karen Golz | Analog Devices | 63 | |
| Anantha Chandrakasan | Analog Devices | 49 | |
| Ali Husain | Analog Devices | N/A | |
| Christopher Twomey | Tandem Diabetes Care | 58 | |
| Julie Shimer | NETGEAR | 65 | |
| Charles Lathrop | Asure Software | 61 | |
| Sanjay Mehrotra | Western Digital | 55 | |
| Andrew Krakauer | Teleflex Incorporated | 66 | |
| Christopher Genualdi | NETGEAR | N/A | |
| Michael Lambert | Western Digital | 69 | |
| Adrian Pertierra | Asure Software | 45 | |
Management Performance
| Return On Equity | -316.72 | |||
| Return On Asset | -136.86 |
Kintara Therapeutics Leadership Team
Elected by the shareholders, the Kintara Therapeutics' board of directors comprises two types of representatives: Kintara Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kintara. The board's role is to monitor Kintara Therapeutics' management team and ensure that shareholders' interests are well served. Kintara Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kintara Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Scott Praill, CFO and Principal Accounting Officer | ||
| John Bell, Independent Director | ||
| William Garner, Director | ||
| Erich Mohr, Independent Director | ||
| Saiid Zarrabian, Director | ||
| Robert Toth, Director | ||
| Dennis Brown, Chief Scientific Officer, Director | ||
| Jeffrey Bacha, President CEO, Director | ||
| Lynda Cranston, Independent Director | ||
| Robert Hoffman, Independent Director | ||
| Napoleone Ferrara, Director |
Kintara Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Kintara Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -316.72 | |||
| Return On Asset | -136.86 | |||
| Current Valuation | 13.09 M | |||
| Shares Outstanding | 11.46 M | |||
| Shares Owned By Insiders | 1.44 % | |||
| Shares Owned By Institutions | 12.46 % | |||
| Number Of Shares Shorted | 246.63 K | |||
| Price To Earning | (1.68) X | |||
| Price To Book | 3.26 X | |||
| EBITDA | (8.26 M) |
Pair Trading with Kintara Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Kintara Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Kintara Therapeutics will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Baxter International could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Baxter International when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Baxter International - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Baxter International to buy it.
The correlation of Baxter International is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Baxter International moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Baxter International moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Baxter International can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Other Consideration for investing in Kintara Stock
If you are still planning to invest in Kintara Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kintara Therapeutics' history and understand the potential risks before investing.
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |